SCHEMBL3662782

SCHEMBL3662782

CCCC1(c2ccccc2)NC(=O)N(CC(=O)c2ccc(NC(=O)Cc3ccc(S(C)(=O)=O)cc3)cc2)C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.56
MEN1 O00255 2/20 0.56
HDAC6 Q9UBN7 1/20 0.51
LMNA P02545 3/20 0.49
MAPT P10636 2/20 0.49
ALDH1A1 P00352 2/20 0.49
HTT P42858 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
GAA P10253 1/20 0.49
TSHR P16473 1/20 0.49
RORC P51449 2/20 0.49
USP2 O75604 1/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
GFER P55789 1/20 0.44
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3660786 0.89 KMT2A (0.57) KMT2AMEN1HDAC6LMNAMAPT
SCHEMBL3657367 0.87 MEN1 (0.55) KMT2AMEN1LMNARORC
SCHEMBL3660936 0.84 KMT2A (0.60) KMT2AMEN1HDAC6LMNAMAPT
SCHEMBL3663347 0.82 KMT2A (0.58) KMT2AMEN1HDAC6LMNAMAPT
SCHEMBL3655230 0.80 KMT2A (0.53) KMT2AMEN1HDAC6LMNAMAPT
SCHEMBL4121157 0.79 KMT2A (0.55) KMT2AMEN1HDAC6LMNAMAPT
SCHEMBL3658360 0.79 LMNA (0.57) KMT2AMEN1HDAC6LMNAMAPT
SCHEMBL3662888 0.78 KMT2A (0.61) KMT2AMEN1HDAC6LMNAMAPT
SCHEMBL3660710 0.77 KMT2A (0.66) KMT2AMEN1MAPTUSP2CRHBP
SCHEMBL3664165 0.77 KMT2A (0.52) KMT2AMEN1HDAC6LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2212314-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS Novartis AG (CH) 2010-08-04 EP disclosed
WO-2009050200-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS NOVARTIS AG (CH) 2009-04-23 WO disclosed
US-20090099243-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099243-A1 ORGANIC COMPOUNDS SLCO4C1, SLCO1B1, SLCO1B3 KMT2A 2020/4885MEN1 155/4885HDAC6 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.